Aktie A2QAMD CHECKMATE PHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Checkmate Pharmaceuticals, Inc.

Aktien

A2QAMD

US1628181083

CMPI

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Bourse Zurich: rebond technique, le SMI finit au-dessus des 11'500 points
Bourse Zurich: dans le vert, à la faveur d'un rebond technique
Regeneron Completes Checkmate Pharmaceuticals Deal, Triggers $5 Million Milestone Payment to Kuros Biosciences
Kuros reçoit un paiement d'étapes après la cession de Checkmate
Kuros To Receive $5 Million Milestone Payment from Regeneron's Acquisition Of Checkmate
Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment
Checkmate Pharmaceuticals : Completion of Acquisition or Disposition of Assets - Form 8-K
CHECKMATE PHARMACEUTICALS, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
Checkmate Pharmaceuticals, Inc. Appoints Robert E. Landry as Chief Financial Officer
Checkmate Pharmaceuticals, Inc. Announces Board Changes
Checkmate Pharmaceuticals, Inc.(NasdaqGM:CMPI) dropped from NASDAQ Composite Index
Checkmate Pharmaceuticals, Inc.(NasdaqGM:CMPI) dropped from S&P TMI Index
Regeneron Pharmaceuticals, Inc. completed the acquisition of Checkmate Pharmaceuticals, Inc. from Decheng Capital China Life Sciences USD Fund III, L.P., a fund managed by Decheng Capital LLC, Arthur Krieg and others.
University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology Annual Meeting
CHECKMATE PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkmate Pharmaceuticals, Inc. - CMPI
CHECKMATE PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
Checkmate Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2QAMD Aktie
  4. Nachrichten Checkmate Pharmaceuticals, Inc.
  5. Andere Sprachen